Changes in sexual hormone levels of iatrogenic premature ovarian insufficiency and its impact on glucose metabolism

doi:10.3969/j.issn.1006-7795.2024.04.004

Abstract

Abstract: Objective To investigate the changes in sex hormone levels and their effects on glucose metabolism in patients with iatrogenic premature ovarian insufficiency (POI). Methods This study recruited 60 patients aged 20-40 years with iatrogenic POI due to hematopoietic stem cell transplantation (HSCT) and 60 patients with idiopathic POI who visited the Department of Gynecological Endocrinology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University from January 2022 to April 2024. General information collected included height, weight, age, and body mass index (BMI). Laboratory measurements included follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E₂), cortisol (F), total testosterone (TT), free testosterone (FT), fasting plasma glucose (FPG), and fasting insulin (FINS). Results Body weight, BMI, E₂, TT and FT levels were significantly lower in iatrogenic POI patients compared to idiopathic POI patients (all P<0.05). FSH, LH, FINS, and FPG levels were significantly higher in iatrogenic POI patients compared to idiopathic POI patients (all P<0.05). There were no significant differences in age, height, and cortisol levels between iatrogenic and idiopathic POI patients (all P>0.05). The proportion of iatrogenic POI patients with hyperinsulinemia was significantly higher than that of idiopathic POI patients (P=0.025).Conclusions Patients with iatrogenic POI exhibited more severe decreases in sex hormone levels and abnormalities in glucose metabolism compared to those with idiopathic POI, possibly due to greater damage to ovarian function from disease treatment. However, iatrogenic POI can be prevented by ovarian tissue cryopreservation (OTC) which can simultaneously preserve fertility and ovarian endocrine function. Therefore, it is highly necessary for patients undergoing OTC before receiving radiotherapy and chemotherapy.

Key words: iatrogenic, idiopathic, premature ovarian insufficiency, sexual hormones, ovarian tissue cryopreservation, glucose metabolism

CLC Number:

R711

Wang Zecheng, Ruan Xiangyan, Yang Yu, Li Jing, Alfred O. Mueck. Changes in sexual hormone levels of iatrogenic premature ovarian insufficiency and its impact on glucose metabolism[J]. Journal of Capital Medical University, 2024, 45(4): 583-588.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2024.04.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2024/V45/I4/583

References

［1］ Webber L, Davies M, Anderson R, et al. ESHRE guideline: management of women with premature ovarian insufficiency［J］. Hum Reprod, 2016, 31(5): 926-937.
［2］ Gleicher N, Kim A, Weghofer A, et al. Hypoandrogenism in association with diminished functional ovarian reserve［J］. Hum Reprod, 2013, 28(4): 1084-1091.
［3］ Bachmann G, Oza D. Female androgen insufficiency［J］. Obstet Gynecol Clin North Am, 2006, 33(4): 589-598.
［4］ Davis S R, Wahlin-Jacobsen S. Testosterone in women-the clinical significance［J］. Lancet Diabetes Endocrinol, 2015, 3(12): 980-992.
［5］ Ryan J, Scali J, Carrière I, et al. Impact of a premature menopause on cognitive function in later life［J］. BJOG, 2014, 121(13): 1729-1739.
［6］ De Vos M, Devroey P, Fauser B C. Primary ovarian insufficiency［J］. Lancet, 2010, 376(9744): 911-921.
［7］ Vogt E C, Real F G, Husebye E S, et al. Premature menopause and autoimmune primary ovarian insufficiency in two international multi-center cohorts［J］. Endocr Connect, 2022, 11(5): e220024.
［8］中国人体健康科技促进会生育力保护与保存专业委员会, 国际妇科内分泌学会中国妇科内分泌学分会, 北京妇产学会内分泌分会, 等. 卵巢组织冻存移植防治医源性早发性卵巢功能不全临床应用指南［J］. 首都医科大学学报, 2023, 44(5): 695-703.
［9］ Qin Y Y, Jiao X, Simpson J L, et al. Genetics of primary ovarian insufficiency: new developments and opportunities［J］. Hum Reprod Update, 2015, 21(6): 787-808.
［10］刘荣华, 王世宣. 放化疗与早发性卵巢功能不全［J］. 中国实用妇科与产科杂志, 2023, 39(9): 891-896.
［11］ European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, et al. ESHRE guideline: management of women with premature ovarian insufficiency［J］. Hum Reprod, 2016, 31(5): 926-937.
［12］ Ten S, Maclaren N. Insulin resistance syndrome in children［J］. J Clin Endocrinol Metab, 2004, 89(6): 2526-2539.
［13］ Keilholz U, Körbling M, Fehrentz D, et al. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders［J］. Cancer, 1989, 64(3): 641-645.
［14］ Chatterjee R, Mills W, Katz M, et al. Prospective study of pituitary-gonadal function to evaluate short-term effects of ablative chemotherapy or total body irradiation with autologous or allogenic marrow transplantation in post-menarcheal female patients［J］. Bone Marrow Transplant, 1994, 13(5): 511-517.
［15］ Grigg A P, McLachlan R, Zaja J, et al. Reproductive status in long-term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120 mg/kg)［J］. Bone Marrow Transplant, 2000, 26(10): 1089-1095.
［16］ Sanders J E, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation［J］. Blood, 1996, 87(7): 3045-3052.
［17］ Spears N, Lopes F, Stefansdottir A, et al. Ovarian damage from chemotherapy and current approaches to its protection［J］. Hum Reprod Update, 2019, 25(6): 673-693.
［18］ Kim S S. Fertility preservation in female cancer patients: current developments and future directions［J］. Fertil Steril, 2006, 85(1): 1-11.
［19］ Stanczyk F Z, Chaikittisilpa S, Sriprasert I, et al. Circulating androgen levels before and after oophorectomy in premenopausal and postmenopausal women［J］. Climacteric, 2019, 22(2): 169-174.
［20］ Nunes E, Gallardo E, Morgado-Nunes S, et al. Steroid hormone levels in postmenopausal hysterectomised women with and without ovarian conservation: the continuous endocrine function of the ovaries［J］. J Obstet Gynaecol, 2023, 43(1): 2141618.
［21］ Jabara S, Christenson L K, Wang C Y, et al. Stromal cells of the human postmenopausal ovary display a distinctive biochemical and molecular phenotype［J］. J Clin Endocrinol Metab, 2003, 88(1): 484-492.
［22］柳越, 董一, 赵世刚, 等. 女性代谢与生殖健康［J］. 中国科学:生命科学, 2024, 54(1): 116-135.
［23］ Rebar R W, Keator C S. Expanding our knowledge of premature ovarian insufficiency［J］. Fertil Steril, 2021, 115(2): 328-329.
［24］ Kur P, Kolasa-Wołosiuk A, Misiakiewicz-Has K, et al. Sex hormone-dependent physiology and diseases of liver［J］. Int J Environ Res Public Health, 2020, 17(8): 2620.
［25］ Yan H, Yang W B, Zhou F H, et al. Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1［J］. Diabetes, 2019, 68(2): 291-304.
［26］ Anagnostis P, Christou K, Artzouchaltzi A M, et al. Early menopause and premature ovarian insufficiency are associated with increased risk of type 2 diabetes: a systematic review and meta-analysis［J］. Eur J Endocrinol, 2019, 180(1): 41-50.
［27］曹正, 阮祥燕, 翟燕红, 等. 多囊卵巢综合征雄激素质谱检测专家共识［J］. 检验医学, 2023, 38(3): 203-208.
［28］ Davis S R, Baber R, Panay N, et al. Global consensus position statement on the use of testosterone therapy for women［J］. J Clin Endocrinol Metab, 2019, 104(10): 4660-4666.
［29］ Xu L L, Yuan Y, Che Z D, et al. The hepatoprotective and hepatotoxic roles of sex and sex-related hormones［J］. Front Immunol, 2022, 13: 939631.
［30］ Kaczmarek A, Reczuch K, Majda J, et al. The association of lower testosterone level with coronary artery disease in postmenopausal women［J］. Int J Cardiol, 2003, 87(1): 53-57.
［31］ Kim J J, Kim D, Yim J Y, et al. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease［J］. Aliment Pharmacol Ther, 2017, 45(11): 1403-1412.
［32］ Xu Y L, Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): a review of literature［J］. J Healthc Eng, 2022, 2022: 9240569.
［33］ Gambineri A, Pelusi C. Sex hormones, obesity and type 2 diabetes: is there a Link?［J］. Endocr Connect, 2019, 8(1): R1-R9.
［34］ Subramanya V, Zhao D, Ouyang P M A, et al. Association of endogenous sex hormone levels with coronary artery calcium progression among post-menopausal women in the multi-ethnic study of atherosclerosis (Mesa)［J］. J Cardiovasc Comput Tomogr, 2019, 13(1): 41-47.
［35］ Zhao D, Guallar E, Ouyang P M A, et al. Endogenous sex hormones and incident cardiovascular disease in post-menopausal women［J］. J Am Coll Cardiol, 2018, 71(22): 2555-2566.
［36］ Casarini L, Crépieux P. Molecular mechanisms of action of FSH［J］. Front Endocrinol (Lausanne), 2019, 10: 305.
［37］ Liu X M, Chan H C, Ding G L, et al. FSH regulates fat accumulation and redistribution in aging through the Gαi/Ca(2+)/CREB pathway［J］. Aging Cell, 2015, 14(3): 409-420.
［38］ Sun D, Bai M Z, Jiang Y Y, et al. Roles of follicle stimulating hormone and its receptor in human metabolic diseases and cancer［J］. Am J Transl Res, 2020, 12(7): 3116-3132.
［39］ Qi X Y, Guo Y J, Song Y F, et al. Follicle-stimulating hormone enhances hepatic gluconeogenesis by GRK2-mediated AMPK hyperphosphorylation at Ser485 in mice［J］. Diabetologia, 2018, 61(5): 1180-1192.
［40］ Geng W X, Yan X R, Du H C, et al. Immunization with FSHβ fusion protein antigen prevents bone loss in a rat ovariectomy-induced osteoporosis model［J］. Biochem Biophys Res Commun, 2013, 434(2): 280-286.
［41］ Yang W Y, Xiao J Z, Yang Z J, et al. Serum lipids and lipoproteins in Chinese men and women［J］. Circulation, 2012, 125(18): 2212-2221.
［42］ Xiong J, Kang S S, Wang Z H, et al. FSH blockade improves cognition in mice with Alzheimer's disease［J］. Nature, 2022, 603(7901): 470-476.
［43］ Kulaksizoglu M, Ipekci S H, Kebapcilar L, et al. Risk factors for diabetes mellitus in women with primary ovarian insufficiency［J］. Biol Trace Elem Res, 2013, 154(3): 313-320.
［44］ Ormazabal V, Nair S, Elfeky O, et al. Association between insulin resistance and the development of cardiovascular disease［J］. Cardiovasc Diabetol, 2018, 17(1): 122.
［45］ ESHRE Guideline Group on Female Fertility Preservation, Anderson R A, Amant F, et al. ESHRE guideline: female fertility preservation［J］. Hum Reprod Open, 2020, 2020(4): hoaa052.
［46］ Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion［J］. Fertil Steril, 2019, 112(6): 1022-1033.

[1]	Wang Zecheng, Ruan Xiangyan, Li Jing, Jiang Lingling, Alfred O.Mueck. he effect of iatrogenic premature ovarian insufficiency on lipid metabolism [J]. Journal of Capital Medical University, 2023, 44(4): 535-539.
[2]	Zhao Yue, Ruan Xiangyan, Gu Muqing, Cheng Jiaojiao, Wang Yuejiao, Jin Jing. Research progresses in fertility and pregnancy management in patients with Turner syndrome [J]. Journal of Capital Medical University, 2023, 44(4): 561-567.